Arsani William Sells 814,874 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) Stock

Design Therapeutics, Inc. (NASDAQ:DSGN) Director Arsani William sold 814,874 shares of the company’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $4.25, for a total value of $3,463,214.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Design Therapeutics Stock Up 3.8 %

NASDAQ DSGN opened at $4.41 on Wednesday. The firm has a market cap of $249.14 million, a price-to-earnings ratio of -4.20 and a beta of 1.83. The business has a 50-day moving average price of $4.01 and a 200-day moving average price of $3.62. Design Therapeutics, Inc. has a twelve month low of $1.94 and a twelve month high of $7.66.

Design Therapeutics (NASDAQ:DSGN) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. Research analysts expect that Design Therapeutics, Inc. will post -1.02 EPS for the current fiscal year.

Hedge Funds Weigh In On Design Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its stake in Design Therapeutics by 2.5% during the second quarter. Bank of New York Mellon Corp now owns 118,110 shares of the company’s stock valued at $396,000 after buying an additional 2,868 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Design Therapeutics by 30.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 21,503 shares of the company’s stock valued at $57,000 after buying an additional 4,983 shares during the last quarter. Federated Hermes Inc. boosted its stake in Design Therapeutics by 317.6% during the fourth quarter. Federated Hermes Inc. now owns 11,999 shares of the company’s stock valued at $32,000 after buying an additional 9,126 shares during the last quarter. Pale Fire Capital SE bought a new position in Design Therapeutics during the fourth quarter valued at approximately $28,000. Finally, Price T Rowe Associates Inc. MD bought a new position in Design Therapeutics during the first quarter valued at approximately $45,000. 56.64% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

DSGN has been the subject of a number of analyst reports. Piper Sandler upgraded Design Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $6.00 to $12.00 in a research report on Tuesday, May 7th. Royal Bank of Canada restated a “sector perform” rating and issued a $4.00 price target on shares of Design Therapeutics in a research report on Tuesday, August 6th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Design Therapeutics currently has an average rating of “Hold” and an average price target of $6.60.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.